StockData

Altimmune vs Entera Bio

ALT and ENTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALT and ENTX compare

Entera Bio is the larger company, worth 1.7 times as much as Altimmune ($523M against $303M).

Entera Bio scores higher on the StockData Score (6 against 4 for Altimmune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALTENTX
Size and price
Market cap$303M$523M
Share price$1.56$3.02
Change, 1 year−61.6%10.2%
Change, 5 years−85.0%−12.0%
Beta (5Y)1.87−0.35
Employees1320
StockData Score
Total score46 (better)
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score26 (better)
Dividend score00
Valuation
P/B0.6× (better)72.0×
FCF yield−25.2%−2.1% (better)
Growth
Revenue growth (TTM)–−100%
Revenue growth, 5Y average−65.3%−35.1% (better)
EPS growth, 5Y average–−17.9%
Profitability
Return on equity−28.9% (better)−139%
Return on invested capital−90.4% (better)−966%
Financial health
Debt / equity0.07 (better)0.00
Interest coverage−28.3×–
Current ratio26.78 (better)8.98
Altman Z-score1.7014.49 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield−36.3%−0.01% (better)
Shareholder yield−36.3%−0.01% (better)
Ownership
Held by institutions77.9%6.2%
Held by insiders0.56%11.3%
Insider net buying, 12 months$452K (better)$141K
Superinvestors holding1–
Short interest, % of float21.8%4.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.